메뉴 건너뛰기




Volumn 22, Issue 2, 2016, Pages 303-307

A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis

Author keywords

fluoroquinolone prophylaxis; hematologic malignancies; Neutropenic fever

Indexed keywords

CARBAPENEM; CEFEPIME; COLISTIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; QUINOLONE DERIVATIVE;

EID: 84959350694     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214567161     Document Type: Review
Times cited : (7)

References (8)
  • 1
    • 3242766680 scopus 로고    scopus 로고
    • Management of fever in neutropenic patients with different risks of complications
    • Klasterky J,. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39 (Suppl 1): S32-S37.
    • (2004) Clin Infect Dis , vol.39 , pp. S32-S37
    • Klasterky, J.1
  • 2
    • 77954338016 scopus 로고    scopus 로고
    • Management of febrile neutropenia: ESMO clinical practice guidelines
    • De Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2010; 21: v252-v256.
    • (2010) Ann Oncol , vol.21 , pp. v252-v256
    • De Naurois, J.1    Novitzky-Basso, I.2    Gill, M.J.3
  • 3
    • 79951816939 scopus 로고    scopus 로고
    • Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America
    • Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-e93.
    • (2011) Clin Infect Dis , vol.52 , pp. e56-e93
    • Freifeld, A.G.1    Bow, E.J.2    Sepkowitz, K.A.3
  • 4
    • 85026940659 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network® (NCCN®) ©National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed 10 October. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc
    • National Comprehensive Cancer Network® (NCCN®). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Prevention and Treatment of Cancer-Related Infections V.2.2014. ©National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed 10 October 2013. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK® NCCN® NCCN GUIDELINES® and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
    • (2013) Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Prevention and Treatment of Cancer-Related Infections V.2.2014
  • 5
    • 20544469254 scopus 로고    scopus 로고
    • Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients
    • Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995.
    • (2005) Ann Intern Med , vol.142 , pp. 979-995
    • Gafter-Gvili, A.1    Fraser, A.2    Paul, M.3
  • 6
    • 33750501379 scopus 로고    scopus 로고
    • Emerging problem pathogens: A review of resistance patterns over time
    • Akova M,. Emerging problem pathogens: a review of resistance patterns over time. Int J Infect Dis 2006; 10 (S2): S3-S8.
    • (2006) Int J Infect Dis , vol.10 , Issue.S2 , pp. S3-S8
    • Akova, M.1
  • 7
    • 2442657715 scopus 로고    scopus 로고
    • "collateral damage" from cephalosporin or quinolone antibiotic therapy
    • Paterson DL,. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38: S341-S345.
    • (2004) Clin Infect Dis , vol.38 , pp. S341-S345
    • Paterson, D.L.1
  • 8
    • 76249105326 scopus 로고    scopus 로고
    • Perils of quinolone exposure in cancer patients: Breakthrough bacteremia with multi-drug resistant organism
    • Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multi-drug resistant organism. Cancer 2010; 116: 967-973.
    • (2010) Cancer , vol.116 , pp. 967-973
    • Rangaraj, G.1    Granwehr, B.P.2    Jiang, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.